Literature DB >> 9119898

Increased hypoxic tolerance by chemical inhibition of oxidative phosphorylation: "chemical preconditioning".

M W Riepe1, F Esclaire, K Kasischke, S Schreiber, H Nakase, O Kempski, A C Ludolph, U Dirnagl, J Hugon.   

Abstract

A short ischemic episode preceding sustained ischemia is known to increase tolerance against ischemic cell death. We report early-onset long-lasting neuroprotection against in vitro hypoxia by preceding selective chemical inhibition of oxidative phosphorylation: "chemical preconditioning." The amplitude of CA1 population spikes (psap) in hippocampal slices prepared from control animals (control slices) was 31 +/- 27% (mean +/- SD) upon 45-min recovery from 15-min in vitro hypoxia. In slices prepared from animals treated in vivo with 20 mg/kg 3-nitropropionate (3-np) 1-24 h prior to slice preparation (preconditioned slices), psap improved to 90 +/- 15% (p < 0.01). Posthypoxic oxygen free radicals were reduced to 65 +/- 10% (mean +/- SD) of control in preconditioned slices (p < 0.05). Posthypoxic neuronal density improved from 52 +/- 15% (mean +/- SD) in control slices to 97 +/- 23% in preconditioned slices (p < 0.001). Glibenclamide, an antagonist at KATP-channels, partly reversed increased hypoxic tolerance. We conclude that chemical preconditioning induces early-onset long-lasting tolerance against in vitro hypoxia. Ultimately, this strategy may be applicable as a neuroprotective strategy in humans.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9119898     DOI: 10.1097/00004647-199703000-00002

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  36 in total

Review 1.  Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use.

Authors:  Ulrich Dirnagl; Kyra Becker; Andreas Meisel
Journal:  Lancet Neurol       Date:  2009-04       Impact factor: 44.182

Review 2.  Hypoxic preconditioning protects against ischemic brain injury.

Authors:  Frank R Sharp; Ruiqiong Ran; Aigang Lu; Yang Tang; Kenneth I Strauss; Todd Glass; Tim Ardizzone; Myriam Bernaudin
Journal:  NeuroRx       Date:  2004-01

Review 3.  Hypoxia--implications for pharmaceutical developments.

Authors:  Lucas Donovan; Scott M Welford; John Haaga; Joseph LaManna; Kingman P Strohl
Journal:  Sleep Breath       Date:  2010-07-14       Impact factor: 2.816

4.  Glycogen accumulation in cardiomyocytes and cardiotoxic effects after 3NPA treatment.

Authors:  Aleksandra Milutinović; Ruda Zorc-Pleskovič
Journal:  Bosn J Basic Med Sci       Date:  2012-02       Impact factor: 3.363

Review 5.  Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel.

Authors:  Andrew P Wojtovich; C Owen Smith; Cole M Haynes; Keith W Nehrke; Paul S Brookes
Journal:  Biochim Biophys Acta       Date:  2013-01-02

Review 6.  Killer proteases and little strokes--how the things that do not kill you make you stronger.

Authors:  Anne E O'Duffy; Yvette M Bordelon; BethAnn McLaughlin
Journal:  J Cereb Blood Flow Metab       Date:  2006-08-09       Impact factor: 6.200

7.  Epsilon PKC is required for the induction of tolerance by ischemic and NMDA-mediated preconditioning in the organotypic hippocampal slice.

Authors:  Ami P Raval; Kunjan R Dave; Daria Mochly-Rosen; Thomas J Sick; Miguel A Pérez-Pinzón
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

Review 8.  Cardioprotection by metabolic shut-down and gradual wake-up.

Authors:  Lindsay S Burwell; Sergiy M Nadtochiy; Paul S Brookes
Journal:  J Mol Cell Cardiol       Date:  2009-03-10       Impact factor: 5.000

9.  Chronic memantine does not block 3-nitropropionic acid-delayed ischaemic tolerance in rat hippocampal slices ex vivo.

Authors:  Tadeusz Frankiewicz; Chris G Parsons
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

10.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.